Amanote Research
Register
Sign In
Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)
Hematological Oncology
- United Kingdom
doi 10.1002/hon.100_2631
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Hematology
Date
June 1, 2019
Authors
A.F. Herrera
U. Ogbu
G. Ku
C.Y. Chuo
Publisher
Wiley
Related search
A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma
American Journal of Hematology
Hematology
Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B- And T-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
R-Ivac Salvage Therapy in Relapsed and Refractory DLBCL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Retrospective Analysis of Real-World Outcomes of Chinese Elder Patients With Diffuse Large B Cell Lymphoma (Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
